Hepatic arterial infusion with irinotecan in patients with liver metastases of colorectal cancer: Results of an extended phase i study

Chemotherapy

Volumn 59, Issue 1, 2013, Pages 66-73

  Eichler, Katrin ^a   Dufas, T ^a   Hammerstingl, R ^a   Gruber Rouh, T ^a   Vogl, T J ^a   Zangos, S ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Colorectal cancer; Hepatic arterial infusion; Irinotecan; Liver metastases; Phase I study

Indexed keywords

IRINOTECAN; BEVACIZUMAB; BILIRUBIN; CAPECITABINE; CREATININE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL LIVER METASTASIS; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; INFECTION; KIDNEY FUNCTION; LEUKOPENIA; LIFE EXPECTANCY; LIVER FUNCTION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; OVERALL SURVIVAL; PAIN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CARCINOMA; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE DURATION; FEMALE; FEVER; KARNOFSKY PERFORMANCE STATUS; LIVER METASTASIS; MALE; METASTATIC COLORECTAL CANCER; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); SIDE EFFECT; SKIN DISEASE; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84879764707     PISSN: 00093157     EISSN: 14219794     Source Type: Journal    
DOI: 10.1159/000348579     Document Type: Article

References (32)

1. Adam R, Lucidi V, Bismuth H: Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004; 84: 659-671. (Pubitemid 38388289)
2. Fusai G, Davidson BR: Management of colorectal liver metastases. Colorectal Dis 2003; 5: 2-23. (Pubitemid 36367460)
3. Germer CT, Buhr HJ, Isbert C: Nonoperative ablation for liver metastases. Possibilities and limitations as a curative treatment. Chirurg 2005; 76: 552-554, 556-563.
4. Berber E, Pelley R, Siperstein AE: Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005; 23: 1358-1364.
5. Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG: Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy - local tumor control rate and survival data. Radiology 2004; 230: 450-458. (Pubitemid 38133806)
6. Lee JM, Han JK, Kim SH, Lee JY, Park HS, Eo H, et al: Radiofrequency ablation in the liver using two cooled-wet electrodes in the bipolar mode. Eur Radiol 2005; 15: 2163-2170. (Pubitemid 41403515)
7. Burdio F, Navarro A, Sousa R, Burdio JM, Guemes A, Gonzalez A, et al: Evolving technology in bipolar perfused radiofrequency ablation: assessment of efficacy, predictability and safety in a pig liver model. Eur Radiol 2006; 16: 1826-1834. (Pubitemid 44027387)
8. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237. (Pubitemid 41095086)
9. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, et al: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly highdose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815. (Pubitemid 27074252)
10. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047. (Pubitemid 30162806)
11. Barber FD, Mavligit G, Kurzrock R: Hepatic arterial infusion chemotherapy for metastatic colorectal cancer: a concise overview. Cancer Treat Rev 2004; 30: 425-436. (Pubitemid 38968123)
12. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-977.
13. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, et al: Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 1996; 77: 1254-1262. (Pubitemid 26102322)
14. Finan PJ, Marshall RJ, Cooper EH, Giles GR: Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72: 373-377. (Pubitemid 15034710)
15. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318; discussion 318-321.
16. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5- FU)/folinic acid (FA) (Mayo) vs. weekly highdose 24 h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2002: 512 (abstr).
17. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: 2910-2919. (Pubitemid 27330019)
18. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-260. (Pubitemid 27020581)
19. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, et al: Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939. (Pubitemid 39004350)
20. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, et al: Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 4006-4014.
21. Tappenden P, Jones R, Paisley S, Carroll C: Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007; 11: 1-128, iii-iv.
22. Feliu Batlle J, Cuadrado E, Castro J, Caldes T, Belda C, Sastre J, et al: Irinotecan-cetuximabbevacizumab as a salvage treatment in heavily pretreated metastatic colorectal cancer patients: a retrospective observational study. Chemotherapy 2011; 57: 138-144.
23. Clarkson B, Young C, Dierick W, Kuehn P, Kim M, Berrett A, et al: Effects of continuous hepatic artery infusion of antimetabolites on primary and metastatic cancer of the liver. Cancer 1962; 15: 472-488.
24. Sullivan RD, Norcross JW, Watkins E Jr: Chemotherapy of metastatic liver cancer by prolonged hepatic-artery infusion. N Engl J Med 1964; 270: 321-327.
25. van Riel JM, van Groeningen CJ, Kedde MA, Gall H, Leisink JM, Gruia G, et al: Continuous administration of irinotecan by hepatic arterial infusion: a phase I and pharmacokinetic study. Clin Cancer Res 2002; 8: 405-412. (Pubitemid 34193957)
26. Ensminger WD: Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 2002; 29: 119-125. (Pubitemid 34297282)
27. Czejka M, Kiss A, Koessner C, Terkola R, Ettlinger D, Schueller J: Metabolic activation of irinotecan during intra-arterial chemotherapy of metastatic colorectal cancer. Anticancer Res 2011; 31: 3573-3578.
28. Kemeny N, Gonen M, Sullivan D, Schwartz L, Benedetti F, Saltz L, et al: Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687-2695. (Pubitemid 32441374)
29. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, et al: Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881-4887. (Pubitemid 46223993)
30. Kemeny N, Jarnagin W, Paty P, Gonen M, Schwartz L, Morse M, et al: Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896. (Pubitemid 46223994)
31. van Riel JM, van Groeningen CJ, de Greve J, Gruia G, Pinedo HM, Giaccone G: Continuous infusion of hepatic arterial irinotecan in pretreated patients with colorectal cancer metastatic to the liver. Ann Oncol 2004; 15: 59-63. (Pubitemid 38139605)
32. Skitzki JJ, Chang AE: Hepatic artery chemotherapy for colorectal liver metastases: technical considerations and review of clinical trials. Surg Oncol 2002; 11: 123-135. (Pubitemid 35279440)